Search

everythinglearnresearchcommunity

for

Search:↓

RU58841's legitimacy and sourcing concerns. Users suggest caution and recommend trusted sources over platforms like Amazon.

The effects of Finasteride on hair loss and its side-effects, such as aching balls. The user has been taking it for two years with no changes to the symptom.

The conversation discusses the effectiveness of using finasteride alone versus combining it with minoxidil, ketoconazole, and microneedling for hair loss treatment. It also touches on the affordability and accessibility of hair transplants, with differing opinions on the financial feasibility of such procedures.

The conversation is about a user's hair loss treatment progress using a routine of Avodart (Dutasteride), oral and topical Minoxidil, Ketoconazole shampoo, and microneedling. The user reports no side effects and shows improvement after resuming consistent treatment.

GT20026 is discussed as a potential treatment for hair loss that targets androgen receptors without affecting hormone levels, but it may not promote significant regrowth. It is expected to be available by 2028, with other treatments like Breezula and Clascoterone also mentioned.

Dutasteride mesotherapy is discussed as a potentially effective hair loss treatment with no sexual side effects, requiring less frequent application than daily pills. However, it is not widely popular due to limited availability, high cost, and skepticism about its effectiveness.

PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.

The user is asking if it's safe to use a glass dropper from a finished RU58841 product with a new RU58841 product and if cleaning it with water is sufficient. They are concerned about the quality of the plastic dropper that came with the new product.

GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.

Fluridil was discussed as a hair loss treatment, with some users experiencing side effects like lethargy and chest tightness. Users also mentioned other treatments like RU58841 and finasteride, with mixed opinions on their effectiveness.

The conversation discusses hair loss treatments, specifically asking about clinics in the US that perform dutasteride mesotherapy. Minoxidil, finasteride, and RU58841 are also mentioned.

PP405 shows promise for reactivating hair follicles, with potential maintenance using 5AR inhibitors. Current treatments like Minoxidil and finasteride are effective but have limitations, and there is hope for more effective solutions in the future.

The user is using a regimen of topical finasteride (.025% concentration), minoxidil, Nutrafol, and vitamin D to address hair loss. They experienced initial side effects but reported improvement over 11 weeks and are considering increasing the dosage.

A 35-year-old male experienced significant hair improvement using microneedling, finasteride, minoxidil, and keto shampoo. He adjusted his microneedling routine for better results.

Microneedling can cause a sneezing reflex due to tingling in the nose. Users report this reaction, especially in the temple region.

The user experienced severe side effects from finasteride and is considering a combination therapy including Minoxidil, Tretinoin, microneedling, caffeine, and other ingredients. They are also thinking about adding red light therapy and microneedling once per week.

A topical treatment called 1961, containing multiple products, is discussed for its compatibility with finasteride. It is suggested that 1961 does not negatively affect finasteride's effectiveness and may even enhance its absorption.

The conversation discusses the sale of a premixed KY19382 solution for research purposes, highlighting previous unsuccessful group buys and the formulation process. Prices and purchasing options for KY19382 solutions and powder are provided.

TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.

Injectable GHK-CU and BPC157 were discussed for hair loss, but users did not notice significant hair changes. BPC157 was noted to help with shoulder issues.

The conversation discusses hair regrowth treatments, specifically using finasteride, minoxidil, and microneedling with the Derminator. Users report significant improvements, especially after adding microneedling to their routine.

The user experienced hair regrowth with finasteride and minoxidil but faced libido issues, leading them to try alternatives like novamaine and a low-dose finasteride/minoxidil solution, which still caused side effects. They are considering reducing the solution's volume, stopping finasteride, or using minoxidil alone, while others suggest alternatives like dutasteride or clascoterone.

PP405 is a promising new treatment for hair loss that activates dormant stem cells in hair follicles, potentially bypassing the effects of DHT. It is currently in phase 2 trials and could be available between 2027 and 2030, but it is not considered a definitive cure.

A user shared progress pictures showing successful hair retention using a low-dose topical finasteride (0.008%) combined with minoxidil. Users discussed the effectiveness of the treatment, minimal effective dosing, and avoiding systemic side effects.

A user is considering making a 2% clascoterone lotion from powder due to unavailability in their location. They plan to mix clascoterone powder with retinol lotion and use literature to determine the correct dosage.

The user experienced side effects from finasteride and minoxidil, switched to Nanoxidil with no side effects, and is now on 0.5mg finasteride 3-5 times a week but is concerned about significant hair shedding and lack of new growth. They are seeking encouragement and advice on whether to trust the process.

A 27-year-old Asian male is treating hair loss with 1mg oral finasteride, topical minoxidil twice daily, and 1.5mm microneedling weekly. The discussion is about his progress with these treatments.

The user is experiencing reduced hair shedding and increased hair density after using finasteride, minoxidil, derma rolling, granactive retinoid, and Nizoral, while also taking testosterone and aromatase inhibitors. They question if they are a hyper responder to the treatments, despite mixed feedback from others about visible progress.

Orient Bio is developing a PLGA formulated version of Cyclosporine A to stimulate hair growth without its immunosuppressant effects. Users discuss various treatments like Clascoterone, PP405, minoxidil, and tacrolimus, expressing hope for new developments and sharing personal experiences with these treatments.

The user is using a routine involving microneedling, Minoxidil with tretinoin, a red light cap, scalp massages, Nizoral shampoo, and essence oil shampoo to address hair loss, with visible progress noted. They are considering topical finasteride or dutasteride if progress slows but are cautious due to past side effects.